Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1649 1674 1675
This examiner grants 38% of resolved cases
Aurora M. Fontainhas examines cases in Tech Center 1600 and Art Unit 1649, with 496 resolved cases in her portfolio. The allowance rate of 37.9 percent indicates a rigorous standard for patentability, where applicants must be prepared for significant pushback. Applicants should also be prepared for a median days to allowance of 1190, reflecting a thorough and potentially lengthy examination process. This duration suggests that reaching an agreement on claim scope may take a considerable amount of time.
The data reveals a significant interview lift of 49.2 percent, which is one of the most effective tools for improving the 37.9 percent allowance rate. This high lift suggests that direct communication can clarify technical issues and lead to more favorable outcomes than written responses alone. With 496 resolved cases, the impact of interviews is a well-documented strategy for navigating this examiner's requirements. Practitioners in Art Unit 1649 should consider scheduling an interview as a standard part of their prosecution plan to mitigate the 1190-day median wait.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17932796 | Cladribine regimen for treating progressive forms of Multiple Sclerosis | Non-Final OA | Merck Patent GmbH |
| 18147420 | METHODS AND SYSTEMS OF DIAGNOSING BRAIN INJURY | Final Rejection | Abbott Laboratories |
| 17914817 | Uses of Tau Phosphosites as Biomarkers for Alzheimer's Disease | Final Rejection | Washington University |
| 17640627 | COMPOSITIONS AND METHODS FOR USING SILK-ELASTINLIKE PROTEIN-BASED POLYMERS | Final Rejection | University of Utah Research Foundation |
| 17780846 | MEASUREMENT METHOD AND MEASUREMENT REAGENT FOR ANALYTE USING IMMUNOREACTION | Non-Final OA | SEKISUI MEDICAL CO., LTD. |
| 16980679 | METHODS FOR TREATING OCULAR DISEASES | Non-Final OA | Novartis AG |
| 18414178 | ANTI-TRANSTHYRETIN ANTIBODIES | Non-Final OA | University Health Network |
| 18423352 | ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18058425 | METHODS AND COMPOSITIONS FOR TREATING RETINAL DISEASES AND CONDITIONS | Non-Final OA | Hadasit Medical Research Services and Development Ltd. |
| 16088031 | BIOMARKERS OF PROTEOPATHIES AND USES THEREOF | Final Rejection | Genzyme Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy